DRUG NAME: Doxorubicin pegylated liposomal

Pegylated liposomal doxorubicin (PLD) is a formulation of doxorubicin in polyethylene glycol (PEG) coated Stealth® liposomes. 3 “Pegylation” is the process whereby the doxorubicin-containing liposomes are enclosed within a PEG layer. 2. Pegylation protects the liposomes

  Liposomal, Pegylated, Pegylated liposomal

AHS Provincial High-alert Medication List

liposomal forms of drugs and conventional counterparts (e.g., amphotericin B, amphotericin B-lipid complex, amphotericin B-liposomal, DOXOrubicin HCL, DOXOrubicin-pegylated liposomal, PACLitaxel, PACLitaxel-nab) moderate sedation agents: IV …

  High, Lists, Medication, Alert, Provincial, Liposomal, Pegylated, Pegylated liposomal, Provincial high alert medication list

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Caelyx pegylated liposomal is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of 1.3 m g/m² on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as

  Product, Summary, Characteristics, Summary of product characteristics, Liposomal, Pegylated, Pegylated liposomal

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Combination therapy with pegylated liposomal doxorubicin VELCADE 1mg powder for solution for injectionis administered via intravenous injection at the recommended dose of 1.3mg/m2 body surface area twice weekly for two weeks on days1, 4, 8, and 11 in a 21-daytreatment cycle. This 3-week period is considered a treatment cycle. At least 72hours

  Product, Summary, Characteristics, Summary of product characteristics, Liposomal, Pegylated, Pegylated liposomal

Paclitaxel Protein-Bound (Nab-paclitaxel) (ABRAXANE)

pegylated liposomal doxorubicin Given intravenously every 4 weeks. Risk of cumulative cardiac toxicity. eribulin Given intravenously on days 1 and 8 every 21 days. Primary toxicity includes neutropenia and peripheral neuropathy. ixabepilone Given intravenously every 21 days. May have less activity compared with taxanes, but resulted in less

  Liposomal, Pegylated, Pegylated liposomal

BC Cancer Extravasation Hazard Table

BC Cancer Extravasation Hazard Table (Systemic Therapy Policy III-20) Developed: 1 November 2014 Revised: 1 January 2022 BC Cancer Extravasation Hazard Table

Prior Authorization Program Information*

*refer to member’s medication guide for determination of coverage. Certain drugs on this table may not be covered by certain member plans. **refer to member’s individual policy for inclusion in the prior authorization program